Change of management by using hybrid imaging with radiolabelled choline in biochemical recurrent prostate cancer: a systematic review and a meta-analysis
ConclusionsOur meta-analysis demonstrated that hybrid imaging with radiolabelled choline may change the management in about half of BRPCa patients. However, as for other PET radiopharmaceuticals, large-scale prospective multicentric studies are needed to investigate whether BRPCa patients can benefit from PET-related treatment changes.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Computers | Databases & Libraries | Prostate Cancer | Radiology | Study